Can a standard HIV pill rescue those who got infected on Long-Acting PrEP?

NCT ID NCT06485154

Recruiting now Disease control Sponsor: University of Witwatersrand, South Africa Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a daily combination pill (TLD) as first-line HIV treatment for 100 people who became infected with HIV despite receiving long-acting cabotegravir PrEP in the past year. Researchers will check if the pill can suppress the virus to undetectable levels after 6 months. The goal is to find a reliable treatment option for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tenofovir, Lamivudine, and Dolutegravir (TLD) combination pill
What this could lead to: If successful, this could confirm that a standard daily HIV pill works well for people who get infected despite using long-acting PrEP, offering a reliable treatment option.
What could go wrong: This is a small, single-arm study with only 100 participants, so results may not apply to everyone. Drug resistance from prior PrEP use could reduce effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREVENTION

Contacts and locations

Locations

Africa Health Research Institute (AHRI)
RECRUITING

Durban, KwaZulu-Natal, 3935, South Africa
Desmond Tutu Health Foundation
RECRUITING

Cape Town, Western Cape, 7925, South Africa
Ezintsha, a division of Wits Health Consortium
RECRUITING

Johannesburg, Gauteng, 2193, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.